Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Instil Bio, Inc. (NQ: TIL )

12.17 -0.36 (-2.88%)
Streaming Delayed Price Updated: 3:58 PM EDT, Jul 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 20,031
Open 12.66
Bid (Size) 12.20 (5)
Ask (Size) 12.65 (2)
Prev. Close 12.53
Today's Range 12.05 - 12.67
52wk Range 6.070 - 13.95
Shares Outstanding 3,290,884
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Why ASP Isotopes Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday 
Via InvestorPlace

Performance

YTD
+56.61%
+56.61%
1 Month
+18.26%
+18.26%
3 Month
+16.17%
+16.17%
6 Month
+2.60%
+2.60%
1 Year
+11.43%
+11.43%

More News

Read More
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2024
Via InvestorPlace
TIL Stock Earnings: Instil Bio Beats EPS for Q4 2023
Via InvestorPlace
TIL Stock Earnings: Instil Bio Beats EPS for Q2 2023
Via InvestorPlace
Instil Bio Resumes ITIL-306 Study In Lung, Ovarian, Renal Cancers
Via Benzinga
Instil Bio Reports First Quarter 2024 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Instil Bio Announces Strategic Update
From Instil Bio
Via GlobeNewswire
TIL Stock Earnings: Instil Bio Misses EPS for Q1 2023
Via InvestorPlace
TIL Stock Earnings: Instil Bio Misses EPS for Q3 2023
Via InvestorPlace
Instil Bio Announces Effective Date of 1-for-20 Reverse Stock Split
From Instil Bio
Via GlobeNewswire
Instil Bio Reports Third Quarter 2023 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Instil Bio Announces Poster Presentations of ITIL-306 Preclinical Data at SITC 2023 Annual Meeting
From Instil Bio
Via GlobeNewswire
Instil Bio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For June 29, 2023
Via Benzinga
Instil Bio Announces Oral Presentation of ITIL-306 Preclinical Data at British Society for Gene and Cell Therapy Annual Conference
From Instil Bio
Via GlobeNewswire
Instil Bio Reports First Quarter 2023 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
Instil Bio Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
From Instil Bio
Via GlobeNewswire
NASDAQ:TIL Shareholder Notice: Investigation over Potential Wrongdoing at Instil Bio, Inc.
Via SBWire
Instil Bio Announces Extension of Cash Runway Beyond 2026 with the Consolidation of R&D Operations to its Manchester, U.K. Site
From Instil Bio
Via GlobeNewswire
Instil Bio Announces Resumption of Clinical Trial of CoStAR-TIL Candidate ITIL-306 in Lung, Ovarian, and Renal Cancer
From Instil Bio
Via GlobeNewswire
INSTIL BIO ALERT: Bragar Eagel & Squire, P.C. is Investigating Instil Bio, Inc. on Behalf of Instil Bio Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Why Shares Of Chinese Companies Are Trading Lower? Here Are 54 Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
Stocks That Hit 52-Week Lows On Friday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.